Harpoon Therapeutics snares $70M to focus on cancer immunotherapy

Part of the white-hot cancer immunotherapy space, where cancer patients' own immune system are amped up or refocused on invading antigens, the company focuses on solid tumors and blood cancers.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.